Unpacking Averages: Assessing FDA’s Postmarket Surveillance Under Section 522

Start
Most months, I try to answer a well-focused question. This month, however, I want to simply take a broad look at how FDA conducts its postmarket surveillance study program under Section 522 of the federal Food, Drug, and Cosmetic Act….
By: Epstein Becker & Green
Previous Story

CMMC 2.0: Department of Defense Releases New Proposed DFARS Rule to Implement its Cybersecurity Maturity Model Certification 2.0 Program

Next Story

And T-Mobile Makes Three: More Information Security Guidance for Telecommunications Carriers from the FCC